Dr. Andrew Yates, Ph.D., is the Senior Vice President and Chief Scientific Officer at Artelo Biosciences. With a background in cannabinoid medicinal chemistry from the University of Nottingham, UK, Dr. Yates brings extensive experience from his tenure at AstraZeneca, where he played significant roles in development, commercial strategy, and medical affairs.

His expertise includes managing key multi-billion-dollar products like CRESTOR®, FORXIGA®, and KEYTRUDA®. At Artelo, Dr. Yates is tasked with advancing the company’s research and development, overseeing engagement with the Scientific Advisory Board, and contributing to the executive management team. His focus lies in developing therapies for anorexia, cancer, PTSD, pain, and inflammation, showcasing a commitment to addressing significant unmet medical needs.

Dr. Yates is known for his successful track record in partnership agreements with academia, biotechnology, and pharmaceutical companies, highlighting his collaborative approach to advancing healthcare solutions.